Even in comparison to its direct obesity/ diabetes therapy pharmaceutical peer, LLY at FWD P/E valuations of 58.71x While using the projected adj EPS progress in a CAGR of +65.four% as a result of FY2026, it's https://tiffanyyosg297916.dgbloggers.com/29545746/the-not-lossing-weight-on-wegovy-diaries